Evidence map›Paper›PMID 38769167›Full record

ArticleCell death & disease2024

Deprivation of methionine inhibits osteosarcoma growth and metastasis via C1orf112-mediated regulation of mitochondrial functions.

Xindan Zhang, Zhenggang Zhao, Xuepeng Wang, Shiwei Zhang, Zilong Zhao, Wenbin Feng, Lijun Xu, Junhua Nie, Hong Li, Jia Liu and 8 more

Abstract read
In one paragraph

Article in Cell death & disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. C1orf112 promotes breast cancer growth by modulating the cell cycle.Frontiers in bioengineering and biotechnology · 2026
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Melittin inhibits osteosarcoma growthJournal of Cancer · 2025
    Article
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Xindan ZhangThe School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, China.
Zhenggang ZhaoThe School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, China.
Xuepeng WangThe School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, China.
Shiwei ZhangThe School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, China.
Zilong ZhaoThe School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, China.
Wenbin FengThe School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, China.
Lijun XuThe School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, China.
Junhua NieSouth China University of Technology School of Medicine, Guangzhou, China.
Hong LiBiomedical Laboratory, Guangzhou Jingke Life Science Institute, Guangzhou, China.
Jia LiuSouth China University of Technology School of Medicine, Guangzhou, China.
Gengmiao XiaoThe School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, China.
Yu ZhangDepartment of Orthopedic Oncology, Guangdong Provincial People's Hospital Affiliated to South China University of Technology School of Medicine, Guangzhou, China.
Haomiao LiDepartment of Musculoskeletal Oncology, Center for Orthopedic Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
Ming LuDepartment of Musculoskeletal Oncology, Center for Orthopedic Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
Jialuo MaiGuangzhou Sinogen Pharmaceutical Co., Ltd., Guangzhou, Guangdong Province, China.
Sujin ZhouThe School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, China. zhousj@gdut.edu.cn.
Allan Z ZhaoThe School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, China. azzhao@gdut.edu.cn.ORCID 0000-0003-2136-0972
Fanghong LiThe School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, China. fli@gdut.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteosarcoma is a malignant bone tumor that primarily inflicts the youth. It often metastasizes to the lungs after chemotherapy failure, which eventually shortens patients' lives. Thus, there is a dire clinical need to develop a novel therapy to tackle osteosarcoma metastasis. Methionine dependence is a special metabolic characteristic of most malignant tumor cells that may offer a target pathway for such therapy. Herein, we demonstrated that methionine deficiency restricted the growth and metastasis of cultured human osteosarcoma cells. A genetically engineered Salmonella, SGN1, capable of overexpressing an L-methioninase and hydrolyzing methionine led to significant reduction of methionine and S-adenosyl-methionine (SAM) specifically in tumor tissues, drastically restricted the growth and metastasis in subcutaneous xenograft, orthotopic, and tail vein-injected metastatic models, and prolonged the survival of the model animals. SGN1 also sharply suppressed the growth of patient-derived organoid and xenograft. Methionine restriction in the osteosarcoma cells initiated severe mitochondrial dysfunction, as evident in the dysregulated gene expression of respiratory chains, increased mitochondrial ROS generation, reduced ATP production, decreased basal and maximum respiration, and damaged mitochondrial membrane potential. Transcriptomic and molecular analysis revealed the reduction of C1orf112 expression as a primary mechanism underlies methionine deprivation-initiated suppression on the growth and metastasis as well as mitochondrial functions. Collectively, our findings unraveled a molecular linkage between methionine restriction, mitochondrial function, and osteosarcoma growth and metastasis. A pharmacological agent, such as SGN1, that can achieve tumor specific deprivation of methionine may represent a promising modality against the metastasis of osteosarcoma and potentially other types of sarcomas as well.

Indexed as

Bone NeoplasmsMethionineMitochondriaOsteosarcomaAnimalsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansMiceMice, NudeNeoplasm MetastasisReactive Oxygen SpeciesS-AdenosylmethionineMethionineReactive Oxygen SpeciesS-Adenosylmethionine

Identifiers

PMID38769167
PMCPMC11106329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.